1

October 6, 2026

Henry Levy

By Email: [EMAIL REDACTED]

Dear Henry:

This letter agreement outlines the terms of the agreement between you and the Clarivate group of

companies and their affiliated or related organizations (the “Company”) regarding the

termination of your employment with the Company (the “Agreement”) in connection with the

consummation of the sale of Clarivate’s Life Sciences & Healthcare business (the “Sale”) to

Janus Buyer, LP (“Altaris”). The closing date of the Sale will be the date of termination of your

employment with the Company (the “Separation Date”). Reference is made to the Retention

Agreement, dated as of July 3, 2026, by and between Clarivate Analytics (US) LLC and you (the

“Retention Agreement”).

We have agreed to the following:

•In connection with entering into this Agreement, you acknowledge and agree that, effective

as of the Separation Date, you will automatically resign from all your positions of the

Company, including your positions as President, Life Sciences & Healthcare, and various

corporate director roles, and that you will execute such further documents and instruments as

may be reasonably necessary or appropriate to effectuate such resignations. Effective as of

the Separation Date, you will not be an “executive officer” of the Company for the purposes

of the rules and regulations of the U.S. Securities and Exchange Commission or an “officer”

of the Company for purposes of Section 16 of the Securities Exchange Act of 1934, as

amended.

To the extent you are enrolled in the Company’s medical, dental, vision and/or health savings

account as of the Separation Date, your enrollment in these plans will end on the Separation

Date. All other applicable employee benefits including, without limitation, participation in

the following Company plans shall also terminate as of the Separation Date (if not already

terminated as of the Separation Date): 401(k) plan, dependent care flexible spending account,

health care flexible spending account, life insurance, short- and long-term disability,

management incentive and any paid time off programs. Following the Separation Date, you

will not be entitled to receive any employee benefits from the Company.

•Separation Benefits: Subject to your (i) compliance with your obligations under this

Agreement and the Retention Agreement (including, for the avoidance of doubt, your Offer

Letter and any of the Restrictive Covenants (each as defined in the Retention Agreement) set

forth therein), (ii) continued employment with the Company through the Closing (as defined

in the Retention Agreement), and (iii) execution and non-revocation of the release included

on Attachment A hereto (the “Release”) in accordance with the time periods required therein,

the Company will provide you with the following payments and benefits (collectively, the

“Separation Benefits”):

2

▪RSU Vesting: Any unvested outstanding awards of restricted share units (“RSUs”)

granted under Clarivate’s Amended and Restated 2019 Incentive Award Plan (as may be

amended and restated from time to time, the “Plan”) shall become fully vested effective

as of immediately prior to the Closing. Pursuant to the Retention Agreement, any

unvested performance share units (“PSUs”) will be automatically cancelled upon the

Closing without any right to compensation. The terms and conditions of the Plan and the

award agreements governing your RSUs and PSUs regarding the effect of a termination

of employment shall otherwise remain unchanged and in place.

▪Severance Amount: In addition, if your employment is terminated by Altaris or its

applicable subsidiary or affiliate without Cause (as defined in the Amended and Restated

Executive Severance Plan of Clarivate PLC, as may be amended and restated from time

to time, the “ESP”)) within six (6) months following the Closing (a “Qualifying

Termination”), you will receive a lump sum cash payment in the amount of

$1,851,559.92 (representing the sum of (i) eighteen (18) months’ of base salary and

annual bonus at target under the Company’s Annual Incentive Plan (“AIP”) and (ii) a

lump sum payment equal to the employer portion of the applicable monthly Consolidated

Omnibus Budget Reconciliation Act of 1985 (“COBRA”) premium payment for the

group medical plan in which you were enrolled as of the Separation Date, multiplied by

eighteen (18) months) (collectively, the “Cash Amount”). In addition, if you have not

otherwise been paid a 2026 annual bonus, in the event of your Qualifying Termination,

you will receive an amount equal to your 2026 annual bonus under the AIP, calculated

assuming a full year of service and based on actual performance as of the Closing (as

reflected in the Company’s accruals for the AIP at the time of Closing) (the “Bonus

Amount” and, together with the “Cash Amount”, the “Severance Amount”). The

Severance Amount shall be paid, less applicable deductions and withholdings, within

sixty (60) days of the Separation Date; provided that, prior to such date, you execute and

do not revoke a general release of claims (which may be a re-execution of the Release or

any other release) that the Company and/or Altaris or its subsidiaries may reasonably

require you to execute prior to such date. Notwithstanding anything to the contrary, if

your employment with the Company or Altaris or its subsidiaries terminates for any

reason other than a Qualifying Termination, you will have no right to, and will forfeit in

its entirety the right to receive, the Severance Amount (or, for the avoidance of doubt,

any portion thereof). For the avoidance of doubt, following the six (6)-month anniversary

of the Closing, you will have no claim or right to the Severance Amount or any other

severance benefits from the Company.

•Expenses: The Company will reimburse you for any authorized business expenses incurred

through the Separation Date, provided they were incurred and submitted in a timely manner

and otherwise in accordance with the Company’s policy.

•Restrictive Covenants: You acknowledge and agree that you are, and will remain, subject to

the Restrictive Covenants.

3

•Remedies: In addition to any other remedies the Company may have, the Company’s

obligations under this Agreement shall terminate if you breach any of the provisions of this

Agreement (including any of the Restrictive Covenants). If, prior to the Separation Date, you

voluntarily terminate or give notice of your intent to voluntarily terminate your employment

or service with the Company, or are terminated for Cause, you will be ineligible to receive

the Separation Benefits or any other benefits under this Agreement.

In addition to any other remedies the Company may have, if, following the Separation Date,

the Company discovers or otherwise learns of a serious conduct or performance issue(s) that

would have provided the Company with Cause to terminate your employment effective

immediately if you were still employed by the Company, you acknowledge and agree that, to

the extent not already received, you will forfeit all benefits provided to you under this

Agreement, including the Separation Benefits, and any amounts or benefits already paid or

received by you under this Agreement shall, upon written request by the Company, become

immediately repayable to the Company.

In consideration for the payments and benefits described herein, you agree to the following:

•Executing Agreement: You agree to execute and return this Agreement within twenty-one

(21) days of the date of this letter and execute and return Attachment A within the

Consideration Period defined in the Release. If you do not execute and return both this

Agreement and Attachment A by the designated deadlines, and/or if you revoke your

acceptance of the Release, this Agreement and your eligibility for a Separation Benefits will

be deemed to be automatically withdrawn and of no legal effect.

•Confidentiality: You agree to treat as confidential and not disclose the terms, contents, or

execution of this Agreement or Attachment A, except as required by law, other than to your

spouse, legal counsel, or tax advisor, with the understanding that s/he will maintain its

confidentiality. This provision is not intended to restrict your legal right to discuss the terms

and conditions of your employment, as more specifically set forth in Section 5 (Protected

Rights) of the Release.

4

•Entire Agreement: This Agreement represents the entire agreement of the parties about the

subject matter hereof, and may not be contradicted by evidence prior, contemporaneous, or

subsequent oral agreements of the parties. Any modifications of the terms of this Agreement

must be made in writing and signed by all parties to the Agreement. All prior understandings

relating to the subject matter of this Agreement, whether oral or written, are hereby

superseded by this Agreement other than any documents expressly referenced in this

Agreement, defined in Attachment A, or incorporated herein by reference. For the avoidance

of doubt, other than the payments and benefits described in this Agreement, you will not be

entitled to any other payments or benefits, including without limitation under the ESP, the

Retention Agreement or your Offer Letter dated March 31, 2023. Notwithstanding anything

contained herein to the contrary, this Agreement and the Release shall not supersede, but

shall supplement and, where applicable, incorporate and extend, any prior confidentiality,

non-competition and non-solicitation agreements and provisions (including, without

limitation, the Restrictive Covenants) entered into between you and the Company (and any

other non­disclosure or other confidentiality agreement or provision, including those

contained in any bonus, stock grant or other incentive program plan of any kind), and such

obligations shall continue in full force and effect.

Please execute and return this Agreement within twenty-one (21) days (but in no event prior to

the Separation Date) to John Doulamis at John.Doulamis@Clarivate.com.

Let me take this opportunity to express my personal thanks for your services and support and to

wish you every success in your future endeavors.

Sincerely,

/s/ Matti Shem Tov

Matti Shem Tov

Chief Executive Officer

Clarivate Plc

Accepted and Agreed by:

/s/ Henry Levy

Name: Henry Levy

Date: October 6, 2026

5

Attachment A

Release & Separation Terms

Pursuant to the Agreement to which this Release & Separation Terms (the “Release”) is attached,

you hereby agree as follows:

1.Release: In consideration for the payments and benefits described herein and within

the Agreement, on behalf of yourself, your predecessors, heirs, executors,

administrators, successors and assigns, you hereby irrevocably and unconditionally

release and discharge the Company (as that term is defined in the Agreement and

including but not limited to Clarivate Analytics (US) LLC and Clarivate PLC) and its

and their past, present, and future parents, subsidiaries, branches, divisions, and

affiliates, and its and their past, present, and future shareholders, employees, officers,

directors, agents, representatives, fiduciaries and attorneys, individually and in their

official capacities (collectively, the “Released Parties”), from any and all causes of

action, suits, debts, claims, guarantees, liabilities, demands, costs, expenses,

attorneys’ fees, damages, indemnities and obligations of any kind or nature, in law,

equity or otherwise, known and unknown, suspected and unsuspected, disclosed and

undisclosed, foreseeable and unforeseeable, which have existed or may have existed,

or which do exist, at any time prior to and including the date on which you sign this

Release, other than any claims that cannot lawfully be waived. This release includes,

but is not limited to, any claims arising directly or indirectly from or related to your

employment with the Company, including, but not limited to, any claims under

federal, state or local fair employment laws or practices or other employee relations

statutes and amendments, including without limitation: the Civil Rights Acts of 1866

and 1991, Title VII of the Civil Rights Act of 1964 as amended, the Lilly Ledbetter

Fair Pay Act of 2009, 42 U.S.C. § 1981 through §1988, Section 503 of the

Rehabilitation Act of 1973, the Equal Pay Act, the Genetic Information

Nondiscrimination Act, the Age Discrimination in Employment Act of 1967

(“ADEA”), the Older Workers Benefit Protection Act, the Americans with

Disabilities Act or the Americans with Disabilities Act Amendments Act, the Family

and Medical Leave Act, as allowed by law, the Fair Labor Standards Act, the

Immigration Reform and Control Act, the Occupational Safety and Health Act, the

Employee Retirement Income Security Act of 1974, and any claims arising under the

Workers Adjustment and Retraining Notification Act (“WARN”) and any parallel

state or local laws, any and all claims under the Pennsylvania Human Relations Act,

the Pennsylvania Whistleblower Law, the Pennsylvania Public Employee Relations

Act, the Philadelphia Fair Practices Ordinance, including any amendments and their

respective implementing regulations, and any other state or local law (statutory,

regulatory, or otherwise) that may be legally waived and released; however, the

identification of specific statutes is for purposes of example only, and the omission of

any specific statute or law shall not limit the scope of this general release in any

manner, and the constitution of the United States and Pennsylvania, any and all

claims under the ESP, and any applicable state laws that provide for benefits similar

to WARN, any claims pursuant to any other federal, state or local statutes,

regulations, ordinances or executive order including providing for the recovery of

attorneys’ fees or costs (and any and all amendments to the foregoing laws); any

claims based on any rule, common law or public policy; any claims based in contract,

whether oral or written, express or implied; any claims based in tort or other

common-law theories, including claims for wrongful or retaliatory discharge; any

claims for constructive or wrongful discharge, whistleblower protection, intentional

or negligent infliction of emotional distress, assault, battery, defamation, fraud,

6

fraudulent inducement; any claims under any practice, handbook or manual of the

Company, or any other obligation, in each case to the extent allowed by law. You

confirm and acknowledge that the Release and Agreement reflects any and all

separation, severance, bonus, compensation, and/or other payments to which you are

entitled under any applicable plan, agreement or practice.

Further, you understand that this Release does not constitute an admission of

liabilities or wrongdoing on the part of the Released Parties, by whom any liability is

expressly denied.

This Release does not affect or limit your rights to any benefits to which you may

otherwise be entitled pursuant to (i) any relevant 401(k) savings and/or health and

welfare plans (if any); (ii) workers’ compensation or unemployment insurance; (iii)

your entitlement to coverage under the Company’s applicable insurance policies and

to indemnification for liabilities incurred in the execution of your duties to the

Company (including, for the avoidance of doubt, your rights under the Director and

Officer Indemnity Agreement entered into by you with the Company); or (iv) in the

Agreement (including the Separation Benefits) or any grant agreement(s) you have

signed.

You further agree that you waive any and all entitlement to relief, including but not

limited to, monetary damages or equitable relief, with respect to any claim or cause of

action release pursuant to this Agreement.

You acknowledge that you have no knowledge of any medical or other facts that

would give rise to a claim for workers’ compensation benefits with respect to your

employment with the Company, and further acknowledge and agree that, as it relates

to your employment with the Company, the Company has complied in all respects

with its obligations under the Family Medical Leave Act, the Fair Labor Standards

Act, and all Pennsylvania laws pertaining to wage and hour requirements.

2.Return Company Property: Subject to Section 5 (Protected Rights), you will return

all materials, equipment and/or property of the Company, including all confidential

information and trade secrets, and will not retain any copies upon the Separation

Date, excluding, for the avoidance of doubt, any materials, equipment and/or property

acquired by Altaris in connection with the Sale.

3.Reasonable Cooperation: Following the Separation Date, you agree to make

yourself reasonably available to cooperate in good faith with the Company regarding

subpoenas, investigations, litigation, arbitration, government inquiries, or any other

proceedings/claims made against the Company. The Company will reimburse you for

reasonable travel costs related to such participation.

4.Post-Employment Obligations:

i.You re-acknowledge and reaffirm the confidentiality, non-disclosure and

employee invention and assignment obligations set forth in your signed 

Clarivate Confidential Information and Invention Assignment Agreement

(“Confidentiality Agreement”).

7

ii.You re-acknowledge and reaffirm your non-solicitation (of both customers

and employees) and non-compete obligations outlined in your Non-

Competition and Non-Solicitation Agreement (“Non-Compete Agreement”).

iii.You acknowledge and re-affirm your non-solicitation (of both customers and

employees), non-compete obligations and nondisparagement obligations

outlined in any equity award agreement(s) you may have signed;

iv.You agree that you will not engage in any disparagement of the Company and

will refrain from making any adverse, false, negative, or critical statements,

implied or expressed, concerning the Company or the Released Parties. The

Company agrees to take all reasonable efforts to ensure its executive

leadership and/or board members do not make any statements about you to

any third parties that would in any manner damage your business or personal

reputation. 

v.In addition to any remedies the Company may have in law or in equity, you

will forfeit all benefits under the Agreement and Release in the event you

engage in any of the activities prohibited by the paragraphs related to post-

employment obligations, and you may be obligated to repay the Company for

any benefits previously paid under this Agreement.

5.Protected Rights: Nothing in this Agreement or otherwise, including the release of

claims clause, restricts or prohibits you from initiating communications directly with,

responding to any inquiries from, providing testimony before, providing confidential

information to, reporting possible violations of law or regulation to, from filing a

claim or assisting with an investigation directly with, or from otherwise

communicating with a self-regulatory authority or a government agency or entity,

including the U. S. Equal Employment Opportunity Commission, the Department of

Labor, the National Labor Relations Board, the Department of Justice, the Securities

and Exchange Commission, the Congress, and any agency Inspector General

(collectively, the “Regulators”), or from making other disclosures that are protected

under the whistleblower provisions of state or federal law or regulation. The

Company may not retaliate against the you for any of these activities, and nothing in

this Agreement or otherwise requires you to waive any monetary award or other

payment you might become entitled to from the Regulators (subject to the following

paragraph). You do not need the prior authorization of the Company to engage in

such communications with Regulators, respond to such inquiries from the Regulators,

provide confidential information or documents to the Regulators. or make any such

reports or disclosures to the Regulators. You are not required to notify the Company

that you have engaged in such communications with the Regulators.

Further, nothing in this Agreement or otherwise shall interfere with your right to file a

charge of discrimination or unfair labor practice with or cooperate or participate in an

investigation or proceeding conducted by the Equal Employment Opportunity

Commission or a like charge or complaint with a state or local fair employment or

labor Regulator. However, the consideration provided by this Agreement shall be the

sole relief provided to you and you agree to waive any monetary benefits or recovery

against the Company in connection with any such charge, claim or proceeding

without regard to who has brought such charge, claim or proceeding.

8

Pursuant to the Defend Trade Secrets Act of 2016, you and the Company

acknowledge and agree that you will not have criminal or civil liability under any

federal or state trade secret law for the disclosure of a trade secret that (i) is made (A)

in confidence to a federal, state, or local government official, either directly or

indirectly, or to an attorney and (B) solely for the purpose of reporting or

investigating a suspected violation of law or (ii) is made in a complaint or other

document filed in a lawsuit or other proceeding, if such filing is made under seal. In

addition, and without limiting the preceding sentence, if you file a lawsuit for

retaliation by the Company for reporting a suspected violation of law, you may

disclose the trade secret to your attorney and may use the trade secret information in

the court proceeding, if you (x) file any document containing the trade secret under

seal and (y) do not disclose the trade secret, except pursuant to court order.

6.Tax Treatment: To the maximum extent permitted under all applicable law, the

parties intend that this Agreement will be interpreted and administered to be exempt

from or conform to the requirements of Internal Revenue Code Section 409A

(“Section 409A”). The Agreement is intended to be exempt from or comply with the

provisions of Section 409A so as to prevent the imposition of tax pursuant to Section

409A and shall be interpreted and/or amended to avoid a violation of Section 409A.

However, the Company does not guarantee the tax treatment of any payments or

benefits under this Agreement including, without limitation, under the Internal

Revenue Code and/or any other federal, state, municipal, local or foreign laws,

including Section 409A. You shall be solely responsible for all taxes that result from

any payments due to you under this Agreement.

7.Governing Law: Subject to Section 5 (Protected Rights), the laws of the State of

Pennsylvania will apply to any dispute concerning this Agreement (determined

without regard to the choice of law provisions thereof or the choice of law provisions

of any other jurisdiction that would cause the application of any other law than that of

the Commonwealth of Pennsylvania.  Should any provision of this Agreement be

declared illegal or unenforceable by any court of competent jurisdiction and cannot be

modified to be enforceable, excluding the Post-Employment Obligations set forth in

Section 4, such provision shall immediately become null and void, leaving the

remainder of the Agreement in full force and effect. The Post-Employment

Obligations referenced herein shall be interpreted and enforced in accordance with the

terms contained in Section 4, the Confidentiality Agreement and/or the Non-Compete

Agreement.

8.Material Breach: You will forfeit all payments and benefits under this Agreement if

you materially breach any of the terms of this Agreement. To the extent a payment

has already been made, you may be asked to repay payments already made in

connection with this Agreement.

9

9.Acknowledgement of Rights and Waiver of Claims under the Age

Discrimination in Employment Act (the “ADEA”):

In connection with your release of claims under the ADEA, you further acknowledge

that:

i.You have read and understand this Release in its entirety and have waived

your ADEA claims knowingly and voluntarily in exchange for the benefits set

forth in the Agreement that you would not otherwise have been entitled to

receive;

ii.By giving you this Release, the Company advised you in writing to consult

with an attorney before signing this Release;

iii.Your execution of this Release has not been forced by any employee or agent

of the Company and you have had adequate time outside of the presence of

any Company representative to consider its terms;

iv.You have had an opportunity to engage counsel and to have counsel review,

explain and advise you as to the terms of the Release subsequent to receiving

the Release;

v.The Company has given you up to twenty-one (21) from the date of the

Agreement to consider this Release (the “Consideration Period”);

vi.You understand that you may execute this Release at any time within the

Consideration Period (the “Acceptance Date”). If you choose not to execute

this Release within the Consideration Period, you understand that you will

forfeit the right to receive the Separation Benefits and other benefits provided

in the Agreement. You agree that if there are any changes to the terms of the

Release, whether material or immaterial, such changes will not restart the

running of the Consideration Period; and

vii.You further understand that you may revoke your acceptance of this Release

after signing it by delivering a written notice of your decision to revoke within

seven (7) calendar days after the Acceptance Date (the “Revocation Period”).

You also understand that your written revocation must be sent to John

Doulamis at John.Doulamis@Clarivate.com and that this Release and your

right to receive the Separation Benefits and other benefits outlined in the

Agreement shall be forfeited if you revoke your signature within the seven (7)

calendar day Revocation Period. You acknowledge and agree that this Release

shall become effective on the first day after the seven (7) calendar day

Revocation Period.

BY SIGNING BELOW, I ACKNOWLEDGE THAT I HAVE READ AND UNDERSTOOD

THE TERMS AND CONDITIONS OF THIS RELEASE, AND THAT I AM GIVING UP ANY

RIGHT I MIGHT HAVE TO BRING A CLAIM AGAINST THE COMPANY, INCLUDING

CLAIMS FOR AGE DISCRIMINATION. I ALSO UNDERSTAND THAT I WOULD NOT

RECEIVE THE BENEFITS HEREIN IF I DID NOT KNOWINGLY AND VOLUNTARILY

ENTER INTO THIS AGREEMENT. I FURTHER STATE THAT I AM SIGNING THIS

AGREEMENT AND RELEASE COMPLETELY WILLINGLY AND VOLUNTARILY, AND

10

THERE IS NO MEDICAL OR OTHER CONDITION THAT WOULD PREVENT ME FROM

DOING SO.

I acknowledge and agree that I must return an executed copy of this Release (not sooner than the

Separation Date) to John Doulamis at John.Doulamis@Clarivate.com.

Accepted and Agreed by:

/s/ Henry Levy

Name: Henry Levy

Date: October 6, 2026

Accepted and Agreed by the Company:

/s/ Matti Shem Tov

Name: Matti Shem Tov

Title: Chief Executive Officer Date: October 6, 2026